Fig. 4

Cost-effectiveness acceptability curves of the national Hib vaccine program for the base case and different vaccine price and herd immunity scenarios. Vertical lines represent the national GDP per capita (US$ 8774), upper bound threshold (US$ 4469) by Woods et al. (2016), and lower bound threshold (US$ 1130) by Woods et al. (2016). The probability that adding Hib vaccine into the National Immunization Program is cost-effective for the base case and when reducing the price of Hib vaccine and accounting for the herd immunity from the probabilistic sensitivity analysis (PSA)